Introduction and commentary: Paving the way for biosimilars in oncology

Affiliations

Editorial

Jame Abraham. Semin Oncol. 2013 Dec.

. 2013 Dec:40 Suppl 1:S1-4.

doi: 10.1053/j.seminoncol.2013.09.014. Epub 2013 Oct 4.

¹ Director of Breast Oncology Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH. Electronic address: abrahaj@ccf.org.

No abstract available

Similar articles

Introduction and commentary: paving the way for biosimilars in oncology, part 2: focus on safety and clinical trial considerations.
Abraham J. Abraham J. Semin Oncol. 2014 Feb;41 Suppl 1:S1-2. doi: 10.1053/j.seminoncol.2013.12.003. Epub 2013 Dec 6. Semin Oncol. 2014. PMID: 24560023 No abstract available.
Developing oncology biosimilars: an essential approach for the future.
Abraham J. Abraham J. Semin Oncol. 2013 Dec;40 Suppl 1:S5-24. doi: 10.1053/j.seminoncol.2013.09.015. Semin Oncol. 2013. PMID: 24267944 Review.
Emerging Opportunities and Challenges of Biosimilars in Oncology Practice.
Lyman GH. Lyman GH. J Oncol Pract. 2017 Sep;13(9_suppl):7s-9s. doi: 10.1200/JOP.2017.026831. J Oncol Pract. 2017. PMID: 28898591 No abstract available.
[The development of biosimilars in oncology].
Jiang SY, Shi YK. Jiang SY, et al. Zhonghua Zhong Liu Za Zhi. 2017 Oct 23;39(10):721-725. doi: 10.3760/cma.j.issn.0253-3766.2017.10.001. Zhonghua Zhong Liu Za Zhi. 2017. PMID: 29061013 Chinese.
Biosimilars in oncology: from development to clinical practice.
Rak Tkaczuk KH, Jacobs IA. Rak Tkaczuk KH, et al. Semin Oncol. 2014 Apr;41 Suppl 3:S3-S12. doi: 10.1053/j.seminoncol.2014.03.008. Epub 2014 Mar 13. Semin Oncol. 2014. PMID: 24767633 Review.